Cellectis Stock (NASDAQ:CLLS)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.96

52W Range

$1.70 - $3.77

50D Avg

$2.00

200D Avg

$2.36

Market Cap

$132.47M

Avg Vol (3M)

$49.30K

Beta

3.20

Div Yield

-

CLLS Company Profile


Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

FR

Employees

216

IPO Date

Mar 24, 2015

Website

CLLS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Therapeutics$25.73M--
High Oleic Soyabean Oil-$27.00M$22.90M
ALLO715--$28.50M

Fiscal year ends in Dec 23 | Currency in USD

CLLS Financial Summary


Dec 23Dec 22Dec 21
Revenue$755.00K$19.17M$73.95M
Operating Income$-106.63M$-89.67M$-85.44M
Net Income$-101.06M$-98.69M$-86.28M
EBITDA$-88.10M$-89.67M$-85.44M
Basic EPS$-1.77$-2.17$-1.93
Diluted EPS$-1.77$-2.17$-1.93

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 05, 24 | 1:59 PM
Q1 24May 30, 24 | 2:06 PM
Q3 23Nov 07, 23 | 2:22 PM

Peer Comparison


TickerCompany
SLNOSoleno Therapeutics, Inc.
NRIXNurix Therapeutics, Inc.
CYTCyteir Therapeutics, Inc.
KYMRKymera Therapeutics, Inc.
FHTXFoghorn Therapeutics Inc.
RGNXREGENXBIO Inc.
INBXInhibrx Biosciences, Inc.
LIANLianBio
ERYPPHAXIAM Therapeutics S.A.
SGTXSigilon Therapeutics, Inc.
PASGPassage Bio, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
HCWBHCW Biologics Inc.
IPHAInnate Pharma S.A.
GLUEMonte Rosa Therapeutics, Inc.
DMACDiaMedica Therapeutics Inc.
GNFTGenfit S.A.
ANEBAnebulo Pharmaceuticals, Inc.
KZRKezar Life Sciences, Inc.
STTKShattuck Labs, Inc.
ELYMEliem Therapeutics, Inc.